Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cinclus Pharma Holding AB ( (SE:CINPHA) ) just unveiled an announcement.
Cinclus Pharma Holding AB’s annual general meeting approved a refreshed seven-member board, reappointing several directors while adding three new members and confirming Lennart Hansson as chair. Shareholders also re-elected Öhrlings PricewaterhouseCoopers AB as auditor and set updated fees for board and committee work, underscoring governance continuity.
The meeting decided to retain earnings by paying no dividend for 2025 and authorized the board to issue up to 20 percent new shares, warrants or convertibles to strengthen the balance sheet or fund strategic deals. Investors also backed a new 2026–2029 performance share program for about 17 employees, tying share rewards to personal investment and performance, which aligns management incentives with long-term shareholder value.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a Swedish pharmaceutical company based in Stockholm, focused on developing innovative treatments in the gastrointestinal and related therapeutic areas. The group targets long-term value creation through research-driven drug development, supported by a listed holding structure and an international investor base.
Average Trading Volume: 112,864
Technical Sentiment Signal: Sell
Current Market Cap: SEK554.7M
For an in-depth examination of CINPHA stock, go to TipRanks’ Overview page.